Rein Therapeutics, Inc. · NASDAQ:RNTX
Rein Therapeutics — Investor Presentation (August 2026)
32 slides from Rein Therapeutics's investor presentation, August 2026
Slide 1: Harnessing fibrosis, unleashing life
Harnessing fibrosis, unleashing life Corporate Presentation | August 2026 Copyright © 2026 Rein Therapeutics
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements of Rein Therapeutics, Inc. (“Rein”, the “Company”, “we”, “our” or “us”) within the meaning of the Private Securities Litigation Reform Act of 1995, including statement
Slide 3: Pioneering Best-in-Class Therapies for Pulmonary & Fibrosis Indications
Pioneering Best-in-Class Therapies for Pulmonary & Fibrosis Indications • Clinical-stage biotech company pioneering potential first-in-class multi-pathway therapies in orphan pulmonary and fibrosis indications • LTI-03 is a potential blockbuster treatment which has demonstrated antifibrotic and rege
Slide 4: Therapies for Underserved Fibrosis and Pulmonary Conditions
Therapies for Underserved Fibrosis and Pulmonary Conditions • Phase 1 clinical met primary endpoint; High dose LTI-03 (5mg BID) was well-tolerated with no identified safety issues LTI-03 Phase 2 • Evaluated a robust set of exploratory biomarkers with predictive Idiopathic Pulmonary value of lung hea
Slide 5: Multiple Orphan Disease Programs Ready for Phase Clinical Trials
Multiple Orphan Disease Programs Ready for Phase 2 Clinical Trials Preclinical Phase 1 Phase 2 Phase 3 Upcoming Milestones LTI-03 Idiopathic Pulmonary Fibrosis Phase 2 Initiated; interim read 2026 LTI-011 Loculated Pleural Effusion Malignant Pleural Effusion LTI-05 Cystic Fibrosis Other Programs Mul
Slide 6: Led by Experienced Biotech and Pulmonary Team
Led by Experienced Biotech and Pulmonary Team Key Management and Board of Directors Brian Windsor, Ph.D. Joe von Rickenbach Chief Executive Officer Chairman and Director Cory H. Hogaboam, Ph.D. Bill Fairey Chief Scientific Officer Director Tim Cunningham Alan Musso Chief Financial Officer Director K
Slide 7: LTI-03: A Novel Treatment Designed to Reverse the Course of IPF
LTI-03: A Novel Treatment Designed to Reverse the Course of IPF Copyright © 2026 Rein Therapeutics 7
Slide 8: Idiopathic Pulmonary Fibrosis – a Deadly Diagnosis
Idiopathic Pulmonary Fibrosis – a Deadly Diagnosis • Idiopathic Pulmonary Fibrosis, or IPF, is a fatal age-related disease characterized by progressive scarring in the lungs1 • IPF is part of a larger group of diseases known as Interstitial Lung Diseases, or ILDs, which are diseases characterized by
Slide 9: Sizable Global Opportunity with Potential Upside
Sizable Global Opportunity with Potential Upside • Only 3 drugs are approved for IPF as of 2025 • Ofev®, the global leader, did $4.0B in sales for 20241 • The estimated global market for IPF alone is projected to be $11.7B2 • Other PF and ILDs represent upside for a successful IPF drug • The mechani
Slide 10: Select Competitive Landscape
Select Competitive Landscape1 Company Compound Single or Multi- Mechanism Target Cell Types Clinical Stage pathway Fibroblasts, type 2 Caveolin-1 CSD Epithelial cells, LTI-03 Multi-pathway Aberrant basaloid P2 mimic cells, Macrophages Broad tyrosine Nintedanib Multi-pathway Fibroblasts Approved kina
Slide 11: Caveolin-1 Regulates Proteins Involved in Multiple Fibrosis-Related Pathways
Caveolin-1 Regulates Proteins Involved in Multiple Fibrosis-Related Pathways in the Lung and Other Organs • Caveolin-1 (Cav1) is a regulator of cellular homeostasis • Cav1 regulates many proteins involved in multiple fibrosis pathways • Cav1 effects its regulation through interacting at the Caveolin
Slide 12: LTI-03: the Critical Portion of the CSD Region of Cav1
LTI-03: the Critical Portion of the CSD Region of Cav1 Mimics the Regulatory Activity of Cav1, Affecting a Wide Range of Proteins Involved in Fibrosis • LTI-03 is a seven amino acid peptide comprising a portion of the Cav1 CSD. Substitution/deletion analysis revealed it is the smallest CSD fragment
Slide 13: Antifibrotic Activity: Single dose LTI-03 inhibits multiple profibrotic proteins
Antifibrotic Activity: Single dose LTI-03 inhibits multiple profibrotic proteins similar to Ofev® (Every 12hrs in Precision Cut Lung Slices (PCLS)—Single Patient Sample) • As an antifibrotic, LTI-03 inhibits large panels of profibrotic proteins in a manner similar to the standard of care drug Ofev®
Slide 14: Regenerative Activity: LTI-03 Preserves Critical Progenitor Cells in the Lung
Regenerative Activity: LTI-03 Preserves Critical Progenitor Cells in the Lung (PCLS Studies. Effects 48 Hours After Administration) • Lysotracker dye (Panel A, bright green dots) localizes to AEC2 cells, A the progenitor cells of the lung, which are responsible for making new lung tissue. LTI-03 res
Slide 15: LTI-03: Clinical Evidence Shows Favorable Safety Profile and Potential for Efficacy
LTI-03: Clinical Evidence Shows Favorable Safety Profile and Potential for Efficacy Copyright © 2026 Rein Therapeutics 15
Slide 16: Phase 1a Clinical Trial—Favorable Safety Profile and Well Tolerated
Phase 1a Clinical Trial—at 20 mg and Below, LTI-03 Demonstrated Favorable Safety Profile and was Well Tolerated (Status: Complete) Healthy Human Volunteer Clinical Trial • Objectives • Primary – Safety and Tolerability • Secondary – Pharmacokinetics • Design • Single Ascending Dose (32 subjects / 3
Slide 17: Phase 1b Clinical Trial Design—Focus on Safety, Tolerability, and Biomarkers
Phase 1b Clinical Trial Design—Focus on Safety, Tolerability, and Biomarkers (Status: Complete) Screening LTI-03 Dry Powder Inhalation Follow-Up Up to 21 Days 14 Days 7 Days In Clinic Visits -D21 D1 D7 D14 D21 Bronchoscopy Bronchoscopy Study Design • IPF diagnosis £ 3 years; no previous antifibrotic
Slide 18: Robust Biomarker Evaluation for De-Risking of LTI-03
Robust Biomarker Evaluation for De-Risking of LTI-03 Several Markers Linked to Lung Function • All of the biomarkers selected for evaluation Statistically Significant Biomarkers ü Have literature suggesting their involvement from Phase 1b Trial ü Are primarily found in important cell types in the IP
Slide 19: IL-11: Example of Strong Evidence of LTI-03 Activity and Potential
IL-11: Example of Strong Evidence of LTI-03 Activity and Potential A. IL-11 is highly A B expressed in IPF* B. LTI-03 significantly reduced IL-11 in IPF patients (vs placebo) C. IL-11 is a predictor of prognosis and acute exacerbation in IPF patients* C *Arai T, Hirose M, Kagawa T, Hatsuda K, Inoue
Slide 20: Surfactant Protein D (SPD) is an important biomarker
Surfactant Protein D (SPD) is an important biomarker for the approved IPF drug Ofev®* and now for LTI-03 • SPD is an indicator of epithelial cell health, an important cell type for proper lung function • SPD has been significantly linked to decline in lung function • SPD was reduced by 4% by Ofev ov
Slide 21: Surfactant Protein D (SPD) Reduction
Surfactant Protein D (SPD) Reduction1, 2, 3 Company Trial Compound Percent Reduction Duration of Treatment Phase 1b LTI-03 5% 2 weeks INMARK (P2)1 Nintedanib 4% 12 weeks CAPACITY (P3)2 Pirfenidone 5% 12 weeks 1Maher, T. M., Gisli Jenkins, R., Cottin, V., Nishioka, Y., Noth, I., Selman, M., Song, J.
Slide 22: LTI-03 – Phase 2 Trial Measuring Lung Function
LTI-03 – Phase 2 Trial Measuring Lung Function Primary endpoints 1 2.5 mg LTI-03 capsule BID Safety and tolerability Low-Dose N= 40 LTI-03 5 mg/day measured by incidence of 1 placebo capsule BID 60 treatment emergent N= 1:1 N= 40 Placebo adverse events N=up to 120 2 placebo capsules BID N= High-Dose
Slide 23: Nasdaq: RNTX
Nasdaq: RNTX Copyright © 2026 Rein Therapeutics
Slide 24: Appendix
Appendix Copyright © 2026 Rein Therapeutics 24
Slide 25: Demonstrated Anti-Fibrotic Properties in the 21-day Bleomycin Mouse Model of IPF
Demonstrated Anti-Fibrotic Properties in the 21-day Bleomycin Mouse Model of IPF BLM Trichrome staining (200x) Saline None LTI-03 CP Fibrotic biomarkers The bleomycin mouse model is an established murine model for characterizing and assessing the impact of novel IPF therapies Marudamuthu AS, Bhandar
Slide 26: LTI-03 Attenuates the overexpression of many profibrotic proteins
LTI-03 Attenuates the overexpression of many profibrotic proteins RTK and associated signaling Metabolic signaling ALK(D5F3) * AMPKa **** p-ALK(3B4)(Y1586) *** p-AMPKb1(S108) **** c-Jun * Deptor ** p-c-Myc(T58) ** LDHA ** Herb2/ErbB3 *** p-mTOR **** p-EGFR(Y1173)(53A5) *** p-Raptor **** p-MEK (1/2)
Slide 27: Cohort Two Biomarker Results
Cohort Two Biomarker Results Positive Statistically Statistically Positive Trend dose Biomarker Trend Significant (p<0.05) Significant (p<0.05) C1+C2 dependency C2 C2 C1+C2 Fibroblasts/ myofibroblasts COL1A1 ✓ ✓ ✓ IL-11 ✓ ✓ ✓ CXCL7 ✓ ✓ ✓ ✓ ✓ pSMAD/ tSMAD Basal-like cells TSLP ✓ ✓ ✓ ✓ ✓ GAL7 ✓ ✓ ✓ ✓
Slide 28: If 10µM in vitro is efficacious, what inhaled dose gives the same concentration
If 10µM in vitro is efficacious, what inhaled dose gives the same concentration in lung epithelial lining fluid (ELF) Dose Estimate: Human 10 µM in vitro efficacy 815.91 Da MW 8.16 µg/mL µg/mL from µM solution 25 mL Frohlich 2016 - ELF vol 1 mg dose in device (nominal) 84% % Emitted Dose: J Koleng 3
Slide 29: In Vivo Dose Assessment: Mouse to Human
In Vivo Dose Assessment: Mouse to Human DPI Mouse Study Concentration 0.13 mg/L B MacKenzie 11/23/20 Time 11 min B MacKenzie 11/23/20 Body Weight 0.035 kg B MacKenzie 11/23/20 Minute Volume 0.045 LPM Litrature Vt 0.18mL, f=255 Mouse Delivered Dose 1.84 mg/kg/d Calculated Deposition Fraction 2.6% % M
Slide 30: LTI-01: the First Drug Being Developed for Loculated Pleural Effusion
LTI-01: the First Drug Being Developed for Loculated Pleural Effusion Copyright © 2026 Rein Therapeutics 30
Slide 31: There Are No Approved Drug Treatments for Loculated Pleural Effusion
There Are No Approved Drug Treatments for Loculated Pleural Effusion • Loculated pleural effusion, or LPE occurs when Healthy Lungs Loculated Pleural Effusion fibrotic scar tissue forms in the pleural cavity, preventing effective drainage of fluid Fibrotic scar tissue • LPE is a frequent pneumonia c
Slide 32: Sizeable US and EU Commercial Opportunity with Potential Upside
Sizeable US and EU Commercial Opportunity with Potential Upside Addressable market Current US and EU Opportunity • 30,000 US fibrinolytic patients • Up to 30,000 additional US LPE patients • tPA/DNase priced at $6,700 per patient in US Estimated US + EU • Estimate similar EU market opportunity to US
Rein Therapeutics — Investor Presentation (August 2026) on 6ix